Tools and resources
This resource has been developed to provide practical information and advice on NICE medical technologies guidance on GreenLight XPS for treating benign prostatic hyperplasia.
NICE's adoption and impact team worked with consultant urologists who use GreenLight XPS in NHS organisations to gather their learning and experiences.
The GreenLight XPS procedure involves using a laser to reduce the size of the prostate (see section 2 of the guidance). Using GreenLight XPS requires training and a mentorship scheme for adoption in the NHS.
The benefits of using GreenLight XPS as reported by NHS staff involved in producing this resource include:
cost savings associated with a day‑case procedure
another treatment option for benign prostatic hyperplasia
improved patient experience compared with other treatments: less bleeding, can be done as a day case and under spinal anaesthetic if necessary
safe and fewer initial complications than transurethral resection of the prostate (TURP)
fewer cancelled operations because of less need to access hospital beds.
The learning gained from existing users is presented in this report as a series of examples of current practice. They are not presented as best practice but as real‑life examples of how NHS sites have adopted this technology.
This resource is intended for the sole purpose of supporting the NHS in adopting, evaluating the impact of adopting or further researching this technology. It is complementary to the guidance and was not considered by the medical technologies advisory committee when developing its recommendations.
GreenLight XPS is only recommended in non‑high‑risk patients. However, NICE recommends that specialists using GreenLight XPS in high‑risk patients collaborate in collecting and publishing data for these patients. High‑risk patients are considered to be people who have:
an increased risk of bleeding or
prostates larger than 100 ml or
This page was last updated: